Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma von Schabath, M B, Welsh, E A, Fulp, W J, Chen, L, Teer, J K, Thompson, Z J, Engel, B E, Xie, M, Berglund, A E, Creelan, B C, Antonia, S J, Gray, J E, Eschrich, S A, Chen, D-T, Cress, W D, Haura, E B, Beg, A A

Volltext

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expans... von Gibbons, D.L., Chow, L.Q., Kim, D.-W., Kim, S.-W., Yeh, T., Song, X., Jiang, H., Taylor, R., Karakunnel, J., Creelan, B.

Volltext

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurr... von Socinski, M., Creelan, B., Horn, L., Reck, M., Paz-Ares, L., Steins, M., Felip, E., van den Heuvel, M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Geese, W.J., Bhagavatheeswaran, P., Chen, A., Carbone, D.P.

Volltext

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mu... von Creelan, B.C., Yeh, T., Kim, S.-W., Nogami, N., Kim, D.-W., Chow, L.Q., Kanda, S., Taylor, R., Tang, W., Tang, M., Angell, H.K., Roudier, M.P., Marotti, M., Gibbons, D.L.

Volltext

A Gene Expression Platform to Predict Benefit From Adjuvant External Beam Radiation in Resected Non-Small Cell Lung Cancer von Creelan, B, Eschrich, S.A, Fulp, W.J, Torres-Roca, J.F

Volltext

Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials von Lam, V.K., Hong, D.S., Heymach, J.V., Blumenschein, G., Butler, M.O., Johnson, M., Creelan, B., Gainor, J.F., Govindan, R., Mudad, R., Neal, J., Brophy, F., Fang, F., Hyland, N., Holdich, T., Ma, Y., Trivedi, T., Norry, E., Amado, R.G.

Volltext

Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer von Ahmed, K.A, Grass, G.D, Creelan, B, Gray, J, Kim, S, Dilling, T.J, Antonia, S.J, Perez, B.A

Volltext

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer von Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

Volltext

Abstract No. 139 ▪ FEATURED ABSTRACT Transarterial Chemoperfusion Treatment of Unresectable Pleural Mesothelioma: A Phase 2 Prospective Study von Kis, B., Pereira, M., Kim, J., El-Haddad, G., Choi, J., Fontaine, J., Saltos, A., Creelan, B., Tanvetyanon, T.

Volltext

P1.04-09 Predictive Clinical and Molecular Features of Long-Term Survivors Receiving Immune Checkpoint Inhibitors for Stage 4 Non-Small Cell Lung Cancer von Franke, A., Antonia, S., Haura, E., Chiappori, A., Tanvetyanon, T., Gray, J.E., Creelan, B.

Volltext

MA13.02 Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer von Puri, S., Tanvetyanon, T., Creelan, B., Shafique, M., Saltos, A., Chiappori, A., Haura, E., Thapa, R., Chen, D., Antonia, S., Gray, J.

Volltext

MA05.06 Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study von Creelan, B., Pereira, M., Logeman, J., Morse, B., Jeong, D., El-Haddad, G., Choi, J., Fontaine, J., Tanvetyanon, T., Kis, B.

Volltext

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma von Creelan, Ben C, Antonia, Scott, Noyes, David, Hunter, Terri B, Simon, George R, Bepler, Gerold, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Schell, Michael J, Chiappori, Alberto

Volltext

A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Sma... von Perez, B.A., Kim, S., Dilling, T.J., Latifi, K., Rose, T., Lannon, A., Macmillan, G., Grass, G.D., Chiappori, A., Haura, E.B., Creelan, B., Gray, J., Tanvetyanon, T., Shafique, M., Saltos, A.N., Rosenberg, S.A., Schell, M., Antonia, S.J.

Volltext

84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising... von Creelan, B C, Yeh, T, Kim, S-W, Nogami, N, Kim, D-W, Chow, L Q, Kanda, S, Taylor, R, Tang, W, Tang, M, Angell, H K, Roudier, M P, Marotti, M, Gibbons, D L

Volltext

MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) von Ou, S., Klempner, S., Creelan, B., Hsieh, W.S., Costin, D., Stephens, P.J., Ross, J., Miller, V., Ali, S., Schrock, A.

Volltext

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of Medi4736 in Patients with Locally Advanced, Unresectable, Stage 3 Nsclc Who Have not Progressed Foll... von Creelan, B., Iannotti, N.O., Salamat, M.A., Jayawardene, D., Ballas, M., Stockman, P.K., Antonia, S.J.

Volltext

OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC von Creelan, B., Teer, J., Toloza, E., Mullinax, J., Landin, A., Gray, J., Tanvetyanon, T., Taddeo, M., Noyes, D., Kelley, L., Fang, B., Koomen, J., Sarnaik, A., Kim, S., Haura, E., Antonia, S.

Volltext

Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) von Spigel, D.R., McLeod, M., Hussein, M.A., Waterhouse, D.M., Einhorn, L., Horn, L., Creelan, B., Babu, S., Leighl, N.B., Couture, F., Chandler, J., Goss, G., Keogh, G., Garon, E.B., Blankstein, K.B., Daniel, D.B., Mohamed, M., Li, A., Aanur, N., Jotte, R.

Volltext

P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC von Chiappori, A., Williams, C., Creelan, B., Tanvetyanon, T., Gray, J., Haura, E., Chen, D.T., Thapa, R., Beg, A., Boyle, T., Sangani, M., Morris, E., Tao, A., Hurtado, F., Manenti, L., Castro, J., Antonia, S.

Volltext